Rheumatoid Vasculitis: A Diminishing Yet Devastating Menace
Tóm tắt
Rheumatoid vasculitis (RV) is an unusual complication of long-standing rheumatoid arthritis, which is characterized by the development of necrotizing or leukocytoclastic vasculitis involving small or medium-sized vessels. In this review, we aim to provide an update on the epidemiology, pathogenesis, clinical presentation, and management of this challenging extra-articular manifestation. RV is heterogenous in its clinical presentation depending on the organ and size of blood vessels involved. The most common organs involved are the skin and peripheral nerve. Based on recent population studies, the incidence has significantly decreased with early recognition and the advent of immunosuppressive drugs and biologics; however, the mortality rates remain high. RV remains a serious extra-articular manifestation of RA that needs to be promptly recognized and treated. No consensus is available on treatment, given the ongoing debate of whether the biologics can trigger or treat RV.
Tài liệu tham khảo
Bartels C, Bell C, Rosenthal A, et al. Decline in rheumatoid vasculitis prevalence among US veterans: a retrospective cross-sectional study. Arthritis Rheum. 2009;60(9):2553–7. doi:10.1002/art.24775.
Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis. 1996;55(2):190–2.
Bartels CM, Bridges AJ. Rheumatoid vasculitis: vanishing menace or target for new treatments? Curr Rheumatol Rep. 2010;12(6):414–9. doi:10.1007/s11926-010-0130-1.
Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60(4):288–97.
Flipo RM, Cardon T, Copin MD, et al. ICAM-1, E-selectin, and TNF alpha expression in labial salivary glands of patients with rheumatoid vasculitis. Ann Rheum Dis. 1997;56(1):41–4.
Martens PB, Goronzy JJ, Schaid D, et al. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997;40(6):1106–14.
Yen J, Moore B, Nakajima T, et al. Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193(10):1159–67.
•• Makol A, Crowson CS, Wetter DA, et al. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology (Oxford). 2014;53(5):890–9. doi:10.1093/rheumatology/ket475. This is a retrospective case-control study where 86 RV patients were compared to controls to identify risk factors for development of RV.
Albano SA, Santana-Sahagun E, Weisman M. Cigarette smoking and rheumatoid arthritis. Semin Arthritis Rheum. 2001;31(3):146–59.
Gorman J, David-Vaudey E, Pai M, et al. Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum. 2004;50(11):3476–84.
Turesson C, Schaid DJ, Weyand CM, et al. Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2776–83.
Watts RA, Scott DG. Vasculitis and inflammatory arthritis. Best Pract Res Clin Rheumatol. 2016;30(5):916–31. doi:10.1016/j.berh.2016.10.008.
•• Ntatsaki E, Mooney J, Scott DG, et al. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatology (Oxford). 2014;53(1):145–52. doi:10.1093/rheumatology/ket326. In this study, the clinical manifestations of RV patients (2001–2010) were reviewed and compared to a previous cohort (1988–2000).
Watts RA, Carruthers CA, Symmons DP. The incidence of rheumatoid vasculitis in the Norwich Health Authority. Br J Rheumatol. 1994;33(9):832–3.
Myasoedova E, Crowson CS, Turesson C, et al. Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study. J Rheumatol. 2011;38(6):983–9. doi:10.3899/jrheum.101133.
Genta MS, Genta RM, Gabay C. Systemic rheumatoid vasculitis: a review. Semin Arthritis Rheum. 2006;36(2):88–98.
Pagnoux C, Mahr A, Cohen P, et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore). 2005;84(2):115–28.
van Laar JM, Smit VT, de Beus WM, et al. Rheumatoid vasculitis presenting as appendicitis. Clin Exp Rheumatol. 1998;16(6):736–8.
Sandhu SK, Choy G. Vasculitis of the gallbladder in early rheumatoid arthritis. BMJ Case Rep. 2013; doi:10.1136/bcr-2012-008228.
Souza AW, Rosa DP, Buosi AL, et al. Testicular vasculitis: a rare manifestation of rheumatoid arthritis. Rev Bras Reumatol. 2013;53(4):365–7.
Albada-Kuipers GA, Bruijn JA, Westedt ML, et al. Coronary arteritis complicating rheumatoid arthritis. Ann Rheum Dis. 1986;45(11):963–5.
Kaneko S, Yamashita H, Sugimori Y, et al. Rheumatoid arthritis-associated aortitis: a case report and literature review. Spring. 2014;3:509. doi:10.1186/2193-1801-3-509.
Gravallese EM, Corson JM, Coblyn JS, et al. Rheumatoid aortitis: a rarely recognized but clinically significant entity. Medicine (Baltimore). 1989;68(2):95–106.
Bannatayne GA. Rheumatoid arthritis, its pathology, morbid anatomy and treatment. 2nd ed. Bristol, England: John Wright; 1898. p. 182.
Watts RA, Mooney J, Lane SE, et al. Rheumatoid vasculitis: becoming extinct? Rheumatology (Oxford). 2004;43(7):920–3.
Sharma A, Dhooria A, Aggarwal A, et al. Connective tissue disorder-associated vasculitis. Curr Rheumatol Rep. 2016;18(6):31. doi:10.1007/s11926-016-0584-x.
Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377–84.
Turesson C, Jacobsson LT. Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol. 2004;33(2):65–72.
Radic M, Martinovic Kaliterna D, Radic J. Overview of vasculitis and vasculopathy in rheumatoid arthritis—something to think about. Clin Rheumatol. 2013;32(7):937–42. doi:10.1007/s10067-013-2273-8.
Puéchal X, Said G, Hilliquin P, et al. Peripheral neuropathy with necrotizing vasculitis in rheumatoid arthritis. A clinicopathologic and prognostic study of thirty-two patients. Arthritis Rheum. 1995;38(11):1618–29.
Laskari K, Ahmadi-Simab K, Lamken M, et al. Are anti-cyclic citrullinated peptide autoantibodies seromarkers for rheumatoid vasculitis in a cohort of patients with systemic vasculitis? Ann Rheum Dis. 2010;69(2):469–71.
Coremans IE, Hagen EC, Daha MR, et al. Antilactoferrin antibodies in patients with rheumatoid arthritis are associated with vasculitis. Arthritis Rheum. 1992;35(12):1466–75.
Magro CM, Crowson AN. The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients. J Cutan Pathol. 2003;30(1):1–10.
Sakaue S, Sumitomo S, Kubo K, et al. Tocilizumab-induced leucocytoclastic vasculitis in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2014;53(8):1529–30. doi:10.1093/rheumatology/keu008.
Tanaka A, Hayaishi N, Kondo Y, et al. Severe gangrene accompanied by varicella zoster virus-related vasculitis mimicking rheumatoid vasculitis. Case Rep Dermatol. 2014;6(1):103–7. doi:10.1159/000360979.
Goldman JA, Casey HL, McIlwain H, et al. Limited plasmapheresis in rheumatoid arthritis with vasculitis. Arthritis Rheum. 1979;22(10):1146–50.
Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. Ann Rheum Dis. 2008;67(6):880–4.
• Puechal X, Gottenberg JE, Berthelot JM, et al. Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: results from the AutoImmunity and Rituximab Registry. Arthritis Care Res (Hoboken). 2012;64(3):331–9. doi:10.1002/acr.20689. The authors assessed the outcome of RV patients treated with rituximab and found it to be a suitable therapeutic option to induce remission.
Fujii W, Kohno M, Ishino H, et al. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis. Mod Rheumatol. 2012;22(4):630–4. doi:10.1007/s10165-011-0559-8.
Iijima T, Suwabe T, Sumida K, et al. Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Mod Rheumatol. 2015;25(1):138–42. doi:10.3109/14397595.2013.874748.
Sumida K, Ubara Y, Takemoto F, et al. Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S133.
Watts RA, Carruthers DM, Scott DG. Isolated nailfold vasculitis in rheumatoid arthritis. Ann Rheum Dis. 1995;54(11):927–9.
• Gutiérrez-González LA. Biological therapy-induced systemic vasculitis. Curr Rheumatol Rep. 2016;18(7):39. doi:10.1007/s11926-016-0588-6. This is an excellent review of vasculitis secondary to biologic therapy.
Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;27(1):63–70. doi:10.1097/BOR.0000000000000126.